Advisors

Scientific and Clinical Advisors

 

Eric Sasso, M.D.

Dr. Sasso is currently Vice President, Medical and Scientific Affairs at Crescendo Bioscience. He came to Crescendo from Abbott Laboratories, where as Medical Director, he worked in Early Immunology clinical development and in Humira Medical Affairs, both in Rheumatology and as head of the Dermatology team. Prior to joining Abbott in 2004, he was Associate Professor at the University of Washington, Seattle, where he has remained an Adjunct Associate Professor since 2004. Dr. Sasso earned an A.B. Biochemistry degree at Harvard University, Cambridge, MA, and an M.D. degree from the University of California, San Diego. He trained in internal medicine at McGill University, Montreal, and did fellowships in rheumatology at the University of Washington, and in immunology research at the Virginia Mason Research Center, Seattle. He is board certified in Internal Medicine and Rheumatology and has published extensively in the fields of rheumatology, immunology and dermatology.


Frederic A. Troy II, Ph.D

 
Frederic A. Troy II, Ph.D
Chairman Emeritus
Professor
UC Davis

 

Professor Troy is Professor and Chairman Emeritus of the Department of Biochemistry and Molecular Medicine at the University of California School of Medicine.  He is a member of the UC Davis NIH Comprehensive Cancer Center and of the UCSD Glycobiology Training Facility, and Adjunct Professor of Medicine at the Xiamen University School of Medicine in Xiamen City, China.  He is also co-founder and CEO of SialoGen Therapeutics.

Professor Troy is an internationally renowned expert in the field of glycochemistry and is past president of the professional Society for Glycobiology.  He was formerly on the Editorial Boards of the journals Glycobiology and the Journal of Biological Chemistry and has been an ad hoc reviewer for numerous other leading journals, including PNAS, Biochemistry, Science and Journal of Organic Chemistry, among others.  He is the recipient of numerous international honors, awards and grants, including most recently the Mizutani Glycoscience Foundation Global Research Grant (2013) and a Bill & Melinda Gates Foundation Research Grant (2012), and has over 100 publications in peer-reviewed journals.

Professor Troy received a B.S. in Chemistry from Washington University in St. Louis and a Ph.D. in Chemistry and Biological Chemistry from Purdue University, and completed a Postdoctoral Fellowship in Biological Chemistry and Oncology at the Johns Hopkins University School of Medicine.  He was also a visiting Professor and American Cancer Society-Eleanor Roosevelt International Cancer Fellow in the Dept. of Tumor Biology at the Karolinska institute Medical School in Stockholm, Sweden.


Corporate Advisors


Vern Norviel


Vern Norviel
Partner, Wilson Sonsini
Goodrich & Rosati


Vern Norviel









Rajiv Mahadevan



Rajiv Mahadevan 
CEO, Applied Immunology





Vern Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the patents and innovation counseling practice. Vern has more than two decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine.

Before joining the firm in 2003, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto.

During his career, Vern has authored or prosecuted more than 15 patents that have been litigated in the United States and abroad, and has overseen intellectual property lawsuits throughout the world.

Vern previously was a member of Wilson Sonsini Goodrich & Rosati's Policy Commmittee and currently serves as a member of its Nominating Committee.




Rajiv Mahadevan is currently CEO and Founder of Applied Immunology, which provides contract research laboratory services to support the development of biological therapeutics, vaccines and diagnostics.  He is also CEO and Founder of Impact Dx, an early stage company focused on innovative diagnostic tests addressing large unmet needs in patient management.  He has a broad general management background with experience in sales, business development, strategic planning, operations and program management.  He was an early hire at the Google- and Genentech-funded startup 23andMe, where he led business development efforts to implement the company's genetics platform in research and clinical settings. Prior to this he held various roles of increasing responsibility at Amgen, supporting the development, commercialization, product strategy and partnering of denosumab (Prolia® and XGEVA®), approved in 2010 by the FDA with expected peak annual sales of over $5 billion. He has held roles in licensing at Novo Nordisk, sales at enterprise software company Aftermind and strategy consulting at Arthur D. Little. He has also served as a global health strategist to the Bill & Melinda Gates Foundation. He received an MBA degree from Stanford University and a BA in Molecular & Cell Biology (emphases in Genetics & Immunology) from the University of California at Berkeley.